Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

ROP

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

ROP

AI Research Report

Powered by Claude

Ready to analyze ROP

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings
  • Yahoo·10h ago

    DAT: Truckload freight rates hit two-year highs as diesel costs surge

    PORTLAND, Ore., April 14, 2026 (GLOBE NEWSWIRE) -- Truckload freight volumes rose across all major equipment types in March while a sharp jump in fuel costs pushed spot and contract rates to their highest levels in more than two years, reported DAT Freight & Analytics, provider of the industry's leading load boards and freight analytics. The DAT Truckload Volume Index (TVI), which measures demand for truckload services, increased month over month, reflecting strong early-season demand to move re

  • Yahoo·10h ago

    Oakmark Fund Picks Roper Technologies (ROP) on Varied Growth Drivers

    Oakmark Funds, advised by Harris Associates, released its “Oakmark Fund” first-quarter 2026 investor letter. The objective of the fund is to deliver capital appreciation by investing in diverse large-cap US companies. A copy of the letter can be downloaded here. In the quarter, the Fund (investor class) outperformed the S&P 500 Index, returning -2.47% vs. -4.33% […]

  • Benzinga·1d ago

    Shares of software-related companies are trading higher as the sector rebounds from a recent selloff, with investors stepping back in after sharp declines. The uptick is supported by dip-buying and a reassessment of earlier concerns around valuations and the impact of emerging technologies like artificial intelligence.

  • Yahoo·2d ago

    Roche Explores Degrader Antibody Conjugates To Support Oncology Pipeline

    Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates for cancer treatment. The partnership combines targeted protein degradation with antibody drug conjugation to explore new oncology drug modalities. Roche receives exclusive rights to selected oncology targets, with the agreement including milestone payments and royalties. Roche Holding, trading at around CHF315.6, has a strong oncology franchise and is now adding a fresh...

  • Yahoo·4d ago

    Roper Technologies Insiders Added US$1.95m Of Stock To Their Holdings

    Quite a few insiders have dramatically grown their holdings in Roper Technologies, Inc. ( NASDAQ:ROP ) over the past 12...

  • View all news →
NASDAQMarket closed
ROP
$354.00
$-2.35 (-0.66%)
Open
$356.06
Prev close
$356.35
Day range
$353.44 – $360.58
52W range
— – —
Mkt cap
—
P/E
—
EPS
—
Beta
—
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B2 on 2025-08-08. View all →

Recent insider activity

View all →
  • 44
    28d ago
  • 44
    28d ago
  • 44
    28d ago
  • 44
    28d ago
  • 44
    Mar 12